Trial Profile
A Study Assessing the Impact of Germline DNA Repair Gene Mutations on Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Receiving First-Line Abiraterone and Enzalutamide
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 May 2020
Price :
$35
*
At a glance
- Drugs Abiraterone (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 05 May 2020 Results published in the Annals of Oncology
- 15 Mar 2018 New trial record
- 10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium.